Evidence map›Paper›PMID 36283971›Full record

ArticleAngewandte Chemie (International ed. in English)2022

Reply to Correspondence on "Synergy and Antagonism between Allosteric and Active-Site Inhibitors of Abl Tyrosine Kinase".

Taylor K Johnson, Daniel A Bochar, Nathalie M Vandecan, Jessica Furtado, Michael P Agius, Sameer Phadke, Matthew B Soellner

Open access · greenAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Clinical Pharmacology of Asciminib: A Review.Clinical pharmacokinetics · 2024
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Taylor K JohnsonDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.
Daniel A BocharDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.
Nathalie M VandecanDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.
Jessica FurtadoDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.
Michael P AgiusDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.
Sameer PhadkeDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.
Matthew B SoellnerDepartment of Chemistry, University of Michigan, 930 N. University Ave., Ann Arbor, MI 48109, USA.ORCID 0000-0003-1394-8645
University of Michigan · US

Funding

Conformational Control of Protein KinasesR01GM125881 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MATTHEW B SOELLNER · 2017 to 2026
$2.5M
6 · The paper itself

Abstract

Manley and co-workers provide data demonstrating that, at super-pharmacological concentrations (300 μM), a ternary complex between Abl, asciminib, and ATP-competitive inhibitors is possible. The work in our manuscript concerns the interplay of asciminib (and GNF-2) with ATP-competitive inhibitors at pharmacologically relevant concentrations (C

Indexed as

Drug Resistance, NeoplasmProto-Oncogene Proteins c-ablAdenosine TriphosphateHumansMolecular ConformationMutationAdenosine TriphosphateProto-Oncogene Proteins c-ablAntagonismAsciminibKinase

Identifiers

PMID36283971
OpenAlexW4307342902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.